BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocyte...
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
About this item
Full title
Author / Creator
Publisher
Germany: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Germany: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing a major adverse cardiac event. Dysregulation of epigenetic mechanisms of gene transcription in innate immune cells contributes to CVD development but is currently not targeted by therapies. Apabetalone (RVX-208) is a small molecule inhibi...
Alternative Titles
Full title
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7657365
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7657365
Other Identifiers
ISSN
1868-7075,1868-7083
E-ISSN
1868-7083,1868-7075
DOI
10.1186/s13148-020-00943-0
